Linked Life Data

15650426

Source:http://linkedlifedata.com/resource/pubmed/id/15650426

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15650426rdf:typepubmed:Citationlld:pubmed
pubmed-article:15650426lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C1325725lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0012854lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0042210lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0000932lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0332621lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0052712lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:15650426lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:15650426pubmed:issue12lld:pubmed
pubmed-article:15650426pubmed:dateCreated2005-1-14lld:pubmed
pubmed-article:15650426pubmed:abstractTextRecently, a vaccine consisting of DNA priming followed by boosting with modified vaccinia Ankara (MVA) has provided long-term protection of rhesus macaques against a virulent challenge with a chimera of simian and human immunodeficiency viruses. Here, we report studies on the development of the DNA component for a DNA/MVA HIV vaccine for humans. Specifically, we assess the ability of a codon-optimized Gag-expressing DNA and two noncodon-optimized Gag-Pol-Env-expressing DNAs to prime the MVA booster dose. The codon-optimized DNA expressed virus-like particles (VLPs), whereas one of the noncodon-optimized DNAs expressed VLPs and the other expressed aggregates of HIV proteins. The MVA boost expressed Gag-Pol and Env and produced VLPs. Immunogenicity studies in macaques used one intramuscular prime with 600 microg of DNA and two intramuscular boosts with 1 x 10(8) pfu of MVA at weeks 8 and 30. The codon-optimized and noncodon-optimized DNAs proved similar in their ability to prime anti-Gag T cell responses. The aggregate and VLP-expressing Gag-Pol-Env DNAs also showed no significant differences in their ability to prime anti-Env Ab responses. The second MVA booster dose did not increase the peak CD4 and CD8 T cell responses, but increased anti-Env Ab titers by 40- to 90-fold. MVA-only immunizations elicited 10-100 times lower frequencies of T cells and 2-4 lower titers of anti-Env Ab than the Gag-Pol-Env DNA/MVA immunizations. Based on the breadth of the T cell response and a trend toward higher titers of anti-Env Ab, we are moving forward with human trials of the noncodon-optimized VLP-expressing DNA.lld:pubmed
pubmed-article:15650426pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15650426pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15650426pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15650426pubmed:languageenglld:pubmed
pubmed-article:15650426pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15650426pubmed:citationSubsetIMlld:pubmed
pubmed-article:15650426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15650426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15650426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15650426pubmed:statusMEDLINElld:pubmed
pubmed-article:15650426pubmed:monthDeclld:pubmed
pubmed-article:15650426pubmed:issn0889-2229lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:KlosIu SIuSlld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:McClureHarold...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:MossBernardBlld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:IOVAAAlld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:ButeraSalvato...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:SharmaSunitaSlld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:SmithJames...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:AmaraRama...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:HerndonJames...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:WyattLinda...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:RobinsonHarri...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:MontefioriDav...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:EllenbergerDe...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:CampbellDavid...lld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:PatelMilloniMlld:pubmed
pubmed-article:15650426pubmed:authorpubmed-author:ChennareddiLa...lld:pubmed
pubmed-article:15650426pubmed:issnTypePrintlld:pubmed
pubmed-article:15650426pubmed:volume20lld:pubmed
pubmed-article:15650426pubmed:ownerNLMlld:pubmed
pubmed-article:15650426pubmed:authorsCompleteYlld:pubmed
pubmed-article:15650426pubmed:pagination1335-47lld:pubmed
pubmed-article:15650426pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:meshHeadingpubmed-meshheading:15650426...lld:pubmed
pubmed-article:15650426pubmed:year2004lld:pubmed
pubmed-article:15650426pubmed:articleTitleDNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.lld:pubmed
pubmed-article:15650426pubmed:affiliationEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA.lld:pubmed
pubmed-article:15650426pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15650426pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15650426lld:pubmed